JavaScript required for full functionality. Enable JavaScript to use the interactive analysis tools.
The Price of Remission: This Cancer Drug Saves Lives — but Costs a Fortune. I Wanted to Know Why.
- Publication
- ProPublica
- Author
- David Armstrong
- Published
- May 8, 2025
- BS Score
- 20.51%
- Analysis source
- gemini
The Price of Remission: This Cancer Drug Saves Lives — but Costs a Fortune. I Wanted to Know Why. - gemini analysis on antibsmachine.
Top detected reasoning patterns
- Framing Effect: 2.7%
- Negativity Bias: 1.9%
- Appeal to Authority: 1.9%
- Availability Heuristic: 1.6%
- Special Pleading: 1.5%
- Overconfidence Bias: 1.2%
Topics
Health Care, Pharmaceutical Pricing, Cancer
Keywords
Revlimid, Cancer Drug, Multiple Myeloma, Drug Pricing, Celgene, Fda, Thalidomide